Incidence of metachronous contralateral breast cancer in the Canton of Zurich: a population-based study of the cancer registry

详细信息    查看全文

• 作者：Julia Prater ; Fabio Valeri ; Dimitri Korol…
• 关键词：Metachronous contralateral breast cancer ; Lobular carcinoma ; Incidence rates ; Year of diagnosis ; Follow ; up period
• 刊名：Journal of Cancer Research and Clinical Oncology
• 出版年：2016
• 出版时间：February 2016
• 年：2016
• 卷：142
• 期：2
• 页码：365-371
• 全文大小：470 KB
• 参考文献：Alkner S, Bendahl PO, Ferno M, Manjer J, Ryden L (2011) Prediction of outcome after diagnosis of metachronous contralateral breast cancer. BMC Cancer 11:114. doi:10.​1186/​1471-2407-11-114 PubMed PubMedCentral CrossRef
  Arpino G, Bardou VJ, Clark GM, Elledge RM (2004) Infiltrating lobular carcinoma of the breast: tumor characteristics and clinical outcome. Breast Cancer Res 6:R149–R156. doi:10.​1186/​bcr767 PubMed PubMedCentral CrossRef
  Bernstein JL, Lapinski RH, Thakore SS, Doucette JT, Thompson WD (2003) The descriptive epidemiology of second primary breast cancer. Epidemiology 14:552–558. doi:10.​1097/​01.​ede.​0000072105.​39021.​6d PubMed CrossRef
  Bertelsen L et al (2008) Effect of systemic adjuvant treatment on risk for contralateral breast cancer in the women’s environment, Cancer and Radiation Epidemiology Study. J Natl Cancer Inst 100:32–40. doi:10.​1093/​jnci/​djm267 PubMed CrossRef
  BFS Statistical office (2010) Bilanz der ständigen Wohnbevölkerung, Kanton Zürich, 1971–2010. STAT-TAB Federal Statistical Office Switzerland, Neuchatel
  Bodmer A et al (2015) Breast cancer in younger women in Switzerland 1996–2009: a longitudinal population-based study. Breast 24:112–117. doi:10.​1016/​j.​breast.​2014.​11.​004 PubMed CrossRef
  Bouchardy C et al (2011a) Risk of second breast cancer according to estrogen receptor status and family history. Breast Cancer Res Treat 127:233–241. doi:10.​1007/​s10549-010-1137-z PubMed CrossRef
  Bouchardy C, Lutz J-M, Kühni C (2011b) Cancer in Switzerland: situation and development from 1983 to 2007. Office fédéral de la statistique (OFS), Neuchâtel
  Burstein HJ et al (2014) Adjuvant endocrine therapy for women with hormone receptor–positive breast cancer: American society of clinical oncology clinical practice guideline focused update. J Clin Oncol 32:2255–2269. doi:10.​1200/​jco.​2013.​54.​2258 PubMed CrossRef
  Ceschi M, Bopp M, Dick A, Probst-Hensch N (2009) Krebs im Kanton Zürich, Ein Bericht des Krebsregisters vol Nr. 15. Institut für Sozial- und Präventivmedizin der Universität Zürich im Auftrag der Gesundheitsdirektion des Kantons Zürich, Zürich
  Chen Y, Thompson W, Semenciw R, Mao Y (1999) Epidemiology of contralateral breast cancer. Cancer Epidemiol Biomarkers Prev 8:855–861PubMed
  Chuba PJ, Hamre MR, Yap J, Severson RK, Lucas D, Shamsa F, Aref A (2005) Bilateral risk for subsequent breast cancer after lobular carcinoma-in situ: analysis of surveillance, epidemiology, and end results data. J Clin Oncol 23:5534–5541. doi:10.​1200/​jco.​2005.​04.​038 PubMed CrossRef
  Curtis R et al (2006) New malignancies among cancer survivors: SEER cancer registries, 1973–2000. National Cancer Institute, Bethesda
  Cuzick J, Baum M (1985) Tamoxifen and contralateral breast cancer Lancet 2:282PubMed
  Ess S, Savidan A, Frick H, Rageth C, Vlastos G, Lutolf U, Thurlimann B (2010) Geographic variation in breast cancer care in Switzerland. Cancer Epidemiol 34:116–121. doi:10.​1016/​j.​canep.​2010.​01.​008 PubMed CrossRef
  Font-Gonzalez A et al (2013) Inferior survival for young patients with contralateral compared to unilateral breast cancer: a nationwide population-based study in the Netherlands. Breast Cancer Res Treat 139:811–819. doi:10.​1007/​s10549-013-2588-9 PubMed CrossRef
  Hartman M et al (2007) Incidence and prognosis of synchronous and metachronous bilateral breast cancer. J Clin Oncol 25:4210–4216. doi:10.​1200/​jco.​2006.​10.​5056 PubMed CrossRef
  Jordan VC (2003) Tamoxifen: a most unlikely pioneering medicine. Nat Rev Drug Discov 2:205–213. doi:10.​1038/​nrd1031 PubMed CrossRef
  Kollias J, Ellis IO, Elston CW, Blamey RW (1999) Clinical and histological predictors of contralateral breast cancer. Eur J Surg Oncol 25:584–589. doi:10.​1053/​ejso.​1999.​0711 PubMed CrossRef
  Krebsregister der Kantone Zürich und Zug (2014) Jahresbericht 2013. University Hospital Zurich and University of Zurich, Zürich
  Kurian AW, McClure LA, John EM, Horn-Ross PL, Ford JM, Clarke CA (2009) Second primary breast cancer occurrence according to hormone receptor status. J Natl Cancer Inst 101:1058–1065. doi:10.​1093/​jnci/​djp181 PubMed PubMedCentral CrossRef
  Levi F, Randimbison L, Te VC, La Vecchia C (2001) Contralateral breast cancer in Vaud, Switzerland. Int J Cancer 93:612–613PubMed CrossRef
  Lizarraga IM, Sugg SL, Weigel RJ, Scott-Conner CE (2013) Review of risk factors for the development of contralateral breast cancer. Am J Surg 206:704–708. doi:10.​1016/​j.​amjsurg.​2013.​08.​002 PubMed CrossRef
  Londero AP et al (2014) Synchronous and metachronous breast malignancies: a cross-sectional retrospective study and review of the literature. Biomed Res Int 2014:250727. doi:10.​1155/​2014/​250727 PubMed PubMedCentral CrossRef
  Lorez M, Clough-Gorr K, NICER Working Group Cancer Prevalence Trends in Switzerland: 2000–2020. In: Swiss Public Health Conference, Zurich, 2013
  Narod SA (2014) Bilateral breast cancers. Nat Rev Clin Oncol 11:157–166. doi:10.​1038/​nrclinonc.​2014.​3 PubMed CrossRef
  Nichols HB, Berrington de Gonzalez A, Lacey JV Jr, Rosenberg PS, Anderson WF (2011) Declining incidence of contralateral breast cancer in the United States from 1975 to 2006. J Clin Oncol 29:1564–1569. doi:10.​1200/​JCO.​2010.​32.​7395 PubMed PubMedCentral CrossRef
  Pagani O et al (2014) Adjuvant exemestane with ovarian suppression in premenopausal breast cancer. N Engl J Med 371:107–118. doi:10.​1056/​NEJMoa1404037 PubMed PubMedCentral CrossRef
  Rasmussen CB et al (2014) Incidence of metachronous contralateral breast cancer in Denmark 1978–2009. Int J Epidemiol 43:1855–1864. doi:10.​1093/​ije/​dyu202 PubMed CrossRef
  Rubino C, Arriagada R, Delaloge S, Le MG (2010) Relation of risk of contralateral breast cancer to the interval since the first primary tumour. Br J Cancer 102:213–219. doi:10.​1038/​sj.​bjc.​6605434 PubMed PubMedCentral CrossRef
  Rutqvist LE et al (1991) Contralateral primary tumors in breast cancer patients in a randomized trial of adjuvant tamoxifen therapy. J Natl Cancer Inst 83:1299–1306. doi:10.​1093/​jnci/​83.​18.​1299 PubMed CrossRef
  Sandberg ME, Hall P, Hartman M, Johansson AL, Eloranta S, Ploner A, Czene K (2012a) Estrogen receptor status in relation to risk of contralateral breast cancer-a population-based cohort study. PLoS One 7:e46535. doi:10.​1371/​journal.​pone.​0046535 PubMed PubMedCentral CrossRef
  Sandberg ME, Hartman M, Klevebring D, Eloranta S, Ploner A, Hall P, Czene K (2012b) Prognostic implications of estrogen receptor pattern of both tumors in contralateral breast cancer. Breast Cancer Res Treat 134:793–800. doi:10.​1007/​s10549-012-2096-3 PubMed CrossRef
  Sawyer E et al (2014) Genetic predisposition to in situ and invasive lobular carcinoma of the breast. PLoS Genet 10:e1004285. doi:10.​1371/​journal.​pgen.​1004285 PubMed PubMedCentral CrossRef
  Schaapveld M et al (2008) The impact of adjuvant therapy on contralateral breast cancer risk and the prognostic significance of contralateral breast cancer: a population based study in the Netherlands. Breast Cancer Res Treat 110:189–197. doi:10.​1007/​s10549-007-9709-2 PubMed PubMedCentral CrossRef
  Schmid SM, Pfefferkorn C, Myrick ME, Viehl CT, Obermann E, Schotzau A, Guth U (2011) Prognosis of early-stage synchronous bilateral invasive breast cancer. Eur J Surg Oncol 37:623–628. doi:10.​1016/​j.​ejso.​2011.​05.​006 PubMed CrossRef
  Soran A, Kamali Polat A, Johnson R, McGuire KP (2014) Increasing trend of contralateral prophylactic mastectomy: What are the factors behind this phenomenon? Surgeon. doi:10.​1016/​j.​surge.​2014.​02.​005
  Verkooijen HM et al (2007) Survival after bilateral breast cancer: results from a population-based study. Breast Cancer Res Treat 105:347–357. doi:10.​1007/​s10549-006-9455-x PubMed CrossRef
  Vichapat V, Garmo H, Holmberg L, Fentiman IS, Tutt A, Gillett C, Luchtenborg M (2011a) Prognosis of metachronous contralateral breast cancer: importance of stage, age and interval time between the two diagnoses. Breast Cancer Res Treat 130:609–618. doi:10.​1007/​s10549-011-1618-8 PubMed CrossRef
  Vichapat V, Gillett C, Fentiman IS, Tutt A, Holmberg L, Luchtenborg M (2011b) Risk factors for metachronous contralateral breast cancer suggest two aetiological pathways. Eur J Cancer 47:1919–1927. doi:10.​1016/​j.​ejca.​2011.​05.​004 PubMed CrossRef
  Vichapat V, Garmo H, Holmberg L, Fentiman IS, Tutt A, Gillett C, Luchtenborg M (2012) Patterns of metastasis in women with metachronous contralateral breast cancer. Br J Cancer 107:221–223. doi:10.​1038/​bjc.​2012.​273 PubMed PubMedCentral CrossRef
  Yerushalmi R, Kennecke H, Woods R, Olivotto IA, Speers C, Gelmon KA (2009) Does multicentric/multifocal breast cancer differ from unifocal breast cancer? An analysis of survival and contralateral breast cancer incidence. Breast Cancer Res Treat 117:365–370. doi:10.​1007/​s10549-008-0265-1 PubMed CrossRef
  
• 作者单位：Julia Prater (1)
  Fabio Valeri (1) (2)
  Dimitri Korol (1)
  Sabine Rohrmann (3)
  Silvia Dehler (1)
  
  1. Cancer Registry Zurich and Zug, Zurich, Switzerland
  2. Institute of Primary Care, University of Zurich, University Hospital of Zurich, Zurich, Switzerland
  3. Division of Chronic Disease Epidemiology; Epidemiology, Biostatistics and Prevention Institute, University of Zurich, Hirschengraben 84, 8001, Zurich, Switzerland
  
• 刊物类别：Medicine
• 刊物主题：Medicine & Public Health
  Oncology
  Cancer Research
  Internal Medicine
  Hematology
  
• 出版者：Springer Berlin / Heidelberg
• ISSN：1432-1335

文摘

Purpose To examine the incidence and characteristics of metachronous contralateral breast cancer (CBC) among women in the Canton of Zurich, Switzerland.